Select Your Region
Global
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
- Non-Small Cell Lung Cancer
Trial Status:
Completed
This trial runs in
Cities
- 's-Hertogenbosch
- A Coruña
- Akashi
- Athens
- Atlanta
- Auckland
- Austin
- Avellino
- Aviano
- Avignon
- Baden
- Bakersfield
- Bari
- Beograd
- Berazategui
- Berlin
- Besançon
- Bettendorf
- Billings
- Bordeaux
- Budapest
- Buffalo
- Burbank
- Caen
- Catania
- Chuo City
- Ciudad de Guatemala
- Coimbra
- Columbus
- Créteil
- Detroit
- Dnipropetrovs'k
- Dunedin
- Edmonton
- Eindhoven
- Eugene
- Fairfax
- Farmington
- Florham Park
- Frankfurt am Main
- Fukuoka
- Fullerton
- Gauting
- Gdańsk
- Genova
- Genève
- Goyang-si
- Grand Junction
- Grimsby
- Göteborg
- Halle (Saale)
- Hamilton
- Harvey
- Hayward
- Heidelberg
- Helsinki
- Hemer
- Henderson
- Houston
- Immenhausen
- Ina
- Innsbruck
- İstanbul
- İzmir
- Jacksonville
- Kashiwa
- Kharkiv
- Kobe
- Koto City
- Krung Thep Maha Nakhon
- KZE
- Köln
- La Tronche
- Las Palmas de Gran Canaria
- Las Vegas
- Laval
- Le Mans
- Lille
- Linköping
- Lisboa
- Lombardia
- London
- Lone Tree
- Long Beach
- Los Angeles
- Lucca
- Luzern 16
- Madrid
- Majadahonda
- Manchester
- Marseille
- Matsuyama
- Miami
- Milano
- Milwaukee
- Minneapolis
- Missoula
- Montréal
- Monza
- Moscow
- Mulhouse
- Málaga
- Nagaizumi
- Nagoya
- Napoli
- Natori
- New York
- Nieuwegein
- Norfolk
- Oakland
- Okayama
- Omaha
- Orlando
- Osakasayama
- Oslo
- Otwock
- Oulu
- Padova
- Panamá
- Paramus
- Paris
- Parma
- Peoria
- Pierre-Bénite
- Pisa
- Porto
- Poznań
- Providence
- Pécs
- Quincy
- Recoleta
- Regensburg
- Rennes
- Rio
- Rio Grande do Sul
- rio-cuarto
- Roanoke
- Roma
- Roseville
- Sacramento
- Saint Petersburg
- Sakai
- Salzburg
- Samara
- San Diego
- San Francisco
- San Jose
- San Luis Obispo
- San Marcos
- Santa Clara
- Santa Maria
- Scarborough
- Seongnam-si
- Seoul
- Shinjuku City
- Solna
- South San Francisco
- Sremska Kamenica
- Strasbourg
- Suresnes
- sutton-in-ashfield
- Tacoma
- Taichung City
- Taipei City
- Tampere
- Taoyuan City
- Temuco
- Thermi
- Torrance
- Toulon
- Toulouse
- Tulsa
- Tyler
- Törökbálint
- Ube
- Udine
- Uzhhorod
- Vallejo
- Valparaíso
- Vancouver
- Verona
- Vöcklabruck
- Walnut Creek
- Warszawa
- Windsor
- Zaragoza
- Épagny-Metz-Tessy
- Łódź
Trial Identifier:
NCT02008227 2013-003331-30 GO28915
Trial Summary
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
Hoffmann-La Roche
Sponsor
Phase 3
Phase
NCT02008227 , GO28915 , 2013-003331-30
Trial Identifier
Atezolizumab, Docetaxel
Treatments
Non-Squamous Non-Small Cell Lung Cancer
Condition
Official Title
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
- Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen or combined modality (e.g., chemoradiation) regimen with curative intent
- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria
- Known active or untreated central nervous system (CNS) metastases
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
- Active hepatitis B or hepatitis C
- Prior treatment with docetaxel
- Prior treatment with cluster of differentiation 137 (CD137) agonists, anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA4), anti-programmed death-1 (anti-PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
For the latest version of this information please go to www.forpatients.roche.com